Your SlideShare is downloading. ×
  • Like
Pharma market
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Pharma market

  • 809 views
Published

This presentation is brief introduction of Pharma Market and work pattern of MNCs (GSK is taken as example).This presentation was given by Faheem Siddiqui in Entrepreneur Conference at MBBS …

This presentation is brief introduction of Pharma Market and work pattern of MNCs (GSK is taken as example).This presentation was given by Faheem Siddiqui in Entrepreneur Conference at MBBS campus-Dadu of Sindh University on 09th October-13

Published in Business , Health & Medicine
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
809
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
62
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Pharmaceutical Marketing
  • 2. PAKISTAN PHARMACEUTICALS MARKET  World Pharma Market Worth $300 Billion  Pakistan Pharma MarketWorth $6.4 Billion- 2% of WorldTotal  30 MNCs and 400 national manufacturing units  Share of MNC 45%  Share of NCs is 55%  Growth Rate 12% per annum
  • 3. Top Companies  TOP MNC GlaxoSmithKline holding 12% Market Share  National Company Getz Pharma holding 4% Market Share
  • 4. Top Companies in Pakistan  GSK-GlaxoSmithKline  Pfizer  Abbott  Novartis  Sanofi-Aventis  Roche  Bayer  Eli-Lilly  Johnson & Johnson
  • 5. Top National Companies  Getz  Sami  Hilton  Bosch  Highnoon  Macter  Searle  Wilson
  • 6. Contribution to Economy  600 companies are active in the field  100,000 employees  1% of sales of each company goes to R&D fund of MOH  More than 47000 Registered Drugs  1100 registered Molecules  Almost all are price controlled
  • 7. Types Of Companies  MNCs  National Companies  Marketing/ Franchisee/Third Party
  • 8. New Business Model (outsourcing)  Vikor Pharma  Muller and Phipps  PremierAgencies  Helium
  • 9. Vikor Pharma  Founded in 1979 as Distribution Company  Largest National Phrama Distribution Company in 1985  Most Modern MIS , Booking and delivery System  Branches in Karachi, Lahore , Islamabad, Quetta, Peshawar, Jhelum, Abbo tabad  Country wide Sub Distributors
  • 10. Vikor Pharma  Owe more than 33% share of GSK distribution  Signed an agreement with GSK in July 2011  Promotion of GSK Products with a SalesVolume of PKR. 1 Billion  Product Portfolio  Ceporex, Seroxat, Revitale-B, Zentel, Lotrix, Dependal-M, Tagamet, Piriton, Zyloric
  • 11. Mission Do More Feel Better Live Longer  GlaxoSmithKline – one of the world's leading research-based Pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, Feel them better and live a longer life
  • 12. •Our Values
  • 13. Some Brands of Gsk
  • 14. International Federation of Pharmaceutical Manufacturers & Associations
  • 15. Value of Ethical Promotion of Medicines •Ethical promotion helps ensures that: •Healthcare professionals have access to information they require; •Patients have access to the medicines they need; and •That medicines are prescribed and used to benefit patients worldwide © IFPMA 2013
  • 16. DOs & DON’Ts ALLOWED  Promotional Aids (strict provision)  Items of Medical Utility (strict Provision)  Hosting of Scientific Promotional Meeting  Limited Sponsorship to genuine scientific event  Cultural courtesy cards/gifts(i.e. inexpensive gifts not related to items of medical utility and allowed by local Law)  Meals/Dinners if in connection to an event and secondary  © IFPMA 2013
  • 17. DOs & DON’Ts NOT ALLOWED  Monetary Gifts  Personal Gifts (i.e. flowers, jewelry, cars, etc.)  Recreational Activities (i.e. golf, tickets to sporting events, concert, vacations, etc.)  Sponsoring of family events or paying for a guest/companion  Meals/Dinners if not in connection to an event  Any form of entertainment (i.e. company paid for musical performance during dinner  © IFPMA 2013
  • 18. Marketing Strategies  Human Resource Department  Marketing Department  Training Department  Hiring of Qualified & Skilled Personnel
  • 19. Marketing Strategies Medical Department Sales Management Product Management
  • 20. Marketing Strategies Develop Marketing Strategy & Promo Material Implement in the Field Approval by Medical Department
  • 21. Marketing Strategies  One to one Detailing to HCPs by Medical Rep through When,Why, How  Give Samples/starter packs to Drs  Give Items of Medical Utility for promotion  Participation in International and National Conferences
  • 22. Marketing Strategies  Clinical Meetings  Educational Programs for Drs.  Sponsorship in Conferences and Seminars  Donations to Govt. Hospitals  Participation inTender Business  EconomicalGifts like Pen,Torch,Tissue paper
  • 23. Social Responsibilities  GSK works under IFMPA CODE OF PRACTICE and follows it’s values  GSK is present in more than 100 countries that always value it’s customers .  In GSK all work done in a 100% pure environment , So that their customers are benefitted.  GSK works with NGOs in un-developed countries.  GSK is largest producers of Vaccines in theWorld, works in collaboration with NGOs
  • 24. SWOT ANALYSIS  STRENGHTS  Global Presence in more than 100 countries  Strong financial Position  Number-1 research based MNC in Pakistan  High Quality research Products  Top company in Skin andVaccine segments  Enjoying customer’s faith  Strong , Qualified,TrainedTeam
  • 25. SWOT ANALYSIS  WEAKNESS  Have to follow IFMPA’s Code of Practice  Beaurocratic Style of Management  Lack of Strong Controlling System  Limited Field Force in Specialty Groups  Frequent Shortages of Products
  • 26. SWOT ANALYSIS  OPPORTUNITIES  New research Molecules to be launched  Outsourcing of mature products  Generics Products in Pipeline  Emerging market ofVaccine  Growth oriented FMCG Group
  • 27. SWOT ANALYSIS  THREATS  Uncertain rules and regulations of Govt.  No Patent Law/protection in Pakistan  Increasing Inflation and value of US-$  Increasing Competition by National Cos  Large Field Force of National companies  Unethical Practices of Competitors
  • 28. Unethical Practices in Pharma  Bribing  Pick and Drop Services  Payments of Utility Bills  Heavy Discounts  FOC Goods  Checks/Cash incentives  Expensive Lunch/Dinner
  • 29. Unethical Practices in Pharma  Free Medical Camps  Monthly Salary  Jewelry  Furniture/Fixture  Office Equipment  Expensive Electronic Items
  • 30. Unethical Practices  Expensive Gifts  ExcursionTrips  Vacation Packages  Local and ForeignTrips
  • 31. Unethical Practices  Renovation of Clinic  Partner ship offers  Installment offers  And other Services